Literature DB >> 18309574

Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.

Lokesh Jain1, Erin R Gardner, Jürgen Venitz, William Dahut, William D Figg.   

Abstract

A rapid and sensitive liquid chromatography/tandem mass spectrometric (LC/MS/MS) assay was developed for the quantitative determination of sorafenib in human plasma. Sample pretreatment involved simple protein precipitation by the addition of 0.5 mL acetonitrile, containing internal standard ([2H3, 15N] sorafenib), to 50 microL of plasma sample volume. Separation was achieved on a Waters SymmetryShield RP8 (2.1 mm x 50 mm, 3.5 microm) column at room temperature using an isocratic elution method with acetonitrile/0.1% formic acid in water: 65/35 (v/v) at a flow rate of 0.25 mL/min. Detection was performed using electrospray ionization in positive ion multiple reaction monitoring (MRM) mode by monitoring the ion transitions from m/z 464.9 --> 252.0 (sorafenib) and m/z 469.0 --> 259.0 (internal standard). Calibration curves were linear in the concentration range of 5-2000 ng/mL. The accuracy and precision values, calculated from three different sets of quality control samples analyzed in quintuplicate on six different days, ranged from 92.86% to 99.88% and from 1.19% to 4.53%, respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18309574      PMCID: PMC2276641          DOI: 10.1016/j.jpba.2007.10.027

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

Authors:  Chunrong Yu; Laura M Bruzek; Xue Wei Meng; Gregory J Gores; Christopher A Carter; Scott H Kaufmann; Alex A Adjei
Journal:  Oncogene       Date:  2005-10-20       Impact factor: 9.867

2.  A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.

Authors:  Ming Zhao; Michelle A Rudek; Ping He; Frank-Thorsten Hafner; Martin Radtke; John J Wright; B Douglas Smith; Wells A Messersmith; Manuel Hidalgo; Sharyn D Baker
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-06-23       Impact factor: 3.205

3.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Authors:  Dirk Strumberg; Heike Richly; Ralf A Hilger; Norbert Schleucher; Sonke Korfee; Mitra Tewes; Markus Faghih; Erich Brendel; Dimitris Voliotis; Claus G Haase; Brian Schwartz; Ahmad Awada; Rudolf Voigtmann; Max E Scheulen; Siegfried Seeber
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

4.  Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry.

Authors:  Nehal J Lakhani; Erin R Lepper; Alex Sparreboom; William L Dahut; Jürgen Venitz; William D Figg
Journal:  Rapid Commun Mass Spectrom       Date:  2005       Impact factor: 2.419

5.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Authors:  Li Liu; Yichen Cao; Charles Chen; Xiaomei Zhang; Angela McNabola; Dean Wilkie; Scott Wilhelm; Mark Lynch; Christopher Carter
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

Review 6.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Authors:  Scott Wilhelm; Christopher Carter; Mark Lynch; Timothy Lowinger; Jacques Dumas; Roger A Smith; Brian Schwartz; Ronit Simantov; Susan Kelley
Journal:  Nat Rev Drug Discov       Date:  2006-10       Impact factor: 84.694

  6 in total
  17 in total

1.  The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.

Authors:  AeRang Kim; Cindy McCully; Rafael Cruz; Diane E Cole; Elizabeth Fox; Frank M Balis; Brigitte C Widemann
Journal:  Invest New Drugs       Date:  2010-11-12       Impact factor: 3.850

2.  Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Authors:  Jeong Heo; Caroline J Breitbach; Anne Moon; Chang Won Kim; Rick Patt; Mi Kyung Kim; Yu Kyung Lee; Sung Yong Oh; Hyun Young Woo; Kelley Parato; Julia Rintoul; Theresa Falls; Theresa Hickman; Byung-Geon Rhee; John C Bell; David H Kirn; Tae-Ho Hwang
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

3.  Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.

Authors:  Lie Li; Ming Zhao; Fariba Navid; Keith Pratz; B Doug Smith; Michelle A Rudek; Sharyn D Baker
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-09-09       Impact factor: 3.205

4.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

5.  Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.

Authors:  AeRang Kim; Brigitte C Widemann; Mark Krailo; Nalini Jayaprakash; Elizabeth Fox; Brenda Weigel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2015-04-27       Impact factor: 3.167

6.  Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Bonnie H Hylander; Elizabeth A Repasky; Wen W Ma; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-03       Impact factor: 3.333

7.  Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Bonnie H Hylander; Elizabeth A Repasky; Wen W Ma; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-03       Impact factor: 3.333

8.  A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.

Authors:  Brigitte C Widemann; Aerang Kim; Elizabeth Fox; Sylvain Baruchel; Peter C Adamson; Ashish M Ingle; Julia Glade Bender; Michael Burke; Brenda Weigel; Diana Stempak; Frank M Balis; Susan M Blaney
Journal:  Clin Cancer Res       Date:  2012-09-07       Impact factor: 12.531

9.  Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Authors:  Nilofer S Azad; Jeanny B Aragon-Ching; William L Dahut; Martin Gutierrez; William D Figg; Lokesh Jain; Seth M Steinberg; Maria L Turner; Elise C Kohn; Heidi H Kong
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

10.  Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

Authors:  Jeanny B Aragon-Ching; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Seth M Steinberg; David Draper; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg; William L Dahut
Journal:  BJU Int       Date:  2009-01-09       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.